Mersana Axes Lead ADC Compound, Puts All Its Eggs In NaPi2b Basket
Executive Summary
Mersana Therapeutics has discontinued its lead candidate because of the competitive landscape surrounding HER2-targeted therapies, and will refocus on its only other clinical program, the NaPi2b-targetting ADC XMT-1536 for ovarian cancer and NSCLC.
You may also be interested in...
Finance Watch: Investors Bet Billions On Big Biopharma Offerings
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases
Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.
Mersana Back On Track After Speedy Changes To ADC Program
Following a clinical hold for its lead product, Mersana explains how it re-engineered the program and how it is developing its ADC platform further.